Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 8Hodgkin Disease 6Central Nervous System Neoplasms 4Oligodendroglioma 3Glioma 2Brain Neoplasms 2Astrocytoma 2Radiation Injuries 1Optic Nerve Glioma 1Neurotoxicity Syndromes 1Lymphoma, AIDS-Related 1HIV Infections 1

Interventions

Paclitaxel 4Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Psychiatric Rehabilitation 2Mental Status and Dementia Tests 2Cisplatin 2Amifostine 2Vincristine 1Temozolomide 1Rituximab 1Procarbazine 1Methotrexate 1Memantine 1Magnetic Resonance Spectroscopy 1Diffusion Tensor Imaging 1Cytarabine 1Carboplatin 1Brachytherapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neurotoxicity Syndromes × Procarbazine × Clear all
NCT01399372 2023-07-20

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Radiation Therapy Oncology Group

Phase 2 Completed
91 enrolled 17 charts
Lymphoid

Lymphoma, Radiation Injuries, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡